Ophthalmologic complications of low-dosage tamoxifen in the treatment of breast carcinoma
De Jong-Busnac, M.
Nederlands Tijdschrift Voor Geneeskunde 133(10): 514-516
1989
ISSN/ISBN: 0028-2162 PMID: 2710233 Document Number: 345395
Two out of 20 patients treated for metastatic or non-metastatic breast cancer with tamoxifen (20 mg 2 dd) developed bilateral secondary tapetoretinal degeneration. In one patient in whom the medication was stopped there was still slight progression of degeneration afterwards. In the other patient tamoxifen was continued under strict ophthalmological control. The total doses have been 7.3 g and 43.8 g respectively.
Document emailed within 1 workday
Related Documents
Reslová, T.; Tosner, J.; Vávrová, I.; Resl, M. 1997: Changes in the endometrium in treatment of breast carcinoma with tamoxifen Ceska Gynekologie 62(5): 277-279Gelmann, E.P. 1997: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma Seminars in Oncology 24(1 Suppl 1: S1
Howell, A.; Harland, R.N.; Barnes, D.M.; Baildam, A.D.; Wilkinson, M.J.; Hayward, E.; Swindell, R.; Sellwood, R.A. 1987: Endocrine therapy for advanced carcinoma of the breast: relationship between the effect of tamoxifen upon concentrations of progesterone receptor and subsequent response to treatment Cancer Research 47(1): 300-304
Abdus-Salam, A.A.; Moharson-Bello, I.A.; Eriba, L.O.; Abdus-Salam, R.A. 2013: Metachronus endometrial carcinoma in a seventy five year old woman with carcinoma of the left breast treated with tamoxifen African Journal of Medicine and Medical Sciences 42(3): 271-275
Chiesa, M.Dalla.; Passalacqua, R.; Michiara, M.; Franciosi, V.; Di Costanzo, F.; Bisagni, G.; Camisa, R.; Buti, S.; Tomasello, G.; Cocconi, G. 2007: Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial Acta Bio-Medica: Atenei Parmensis 78(3): 204-209
Lindahl, B.; Andolf, E.; Ingvar, C.; Ranstam, J.; Willén, R. 2008: Adjuvant tamoxifen in breast cancer patients affects the endometrium by time, an effect remaining years after end of treatment and results in an increased frequency of endometrial carcinoma Anticancer Research 28(2b): 1259-1262
Mustacchi, G.; Milani, S.; Pluchinotta, A.; De Matteis, A.; Rubagotti, A.; Perrota, A. 1994: Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly Anticancer Research 14(5b): 2197-2200
Epifani, S.; Lattarulo, S.; Maiorino, R.; Fabiano, G. 2000: Monitoring of postmenopausal women treated with tamoxifen for breast carcinoma Il Giornale di Chirurgia 21(6-7): 310-312
Heirler, F.; de la Motte, S.; Popp, W. 1995: Influence of metronidazole and tamoxifen in a case of otherwise untreated ulcerous breast carcinoma European Journal of Gynaecological Oncology 16(6): 448-452
Semiglazov, V.F.; Maximov, S.Y.; Bulgatova, Y., A.; Meshkova, I.Y.; Chepik, O.F.; Berstein, L.M. 2003: Risk of hyperplasia and endometrial carcinoma in breast cancer patients receiving adjuvant tamoxifen Voprosy Onkologii (Stsburg). 49(2): 198-204
Kelessis, N.G.; Vassilopoulos, P.P.; Galanopoulou, A.V.; Nessiotis, A.G.; Stravolemos, C.M. 2000: Administration of tamoxifen in the perioperative period to patients with breast carcinoma prolongs axillary fluid drainage Anticancer Research 20(2b): 1245-1248
Krejcí, L.; Praus, R.; Brettschneider, I. 1972: Hydron stripes as a new dosage form for ophthalmologic drugs Ceskoslovenska Oftalmologie 28(1): 5-9
Brockmann, B.; Dietzmann, A.; Reitzig, P.; Possinger, K. 1997: Intensification of chemotherapy dosage in metastatic breast carcinoma? Zeitschrift für Arztliche Fortbildung und Qualitatssicherung 91(2): 181-185
Cocconi, G.; Boni, C.; Naldi, N.; Nizzoli, R.; Bozzetti, C. 1989: Exacerbation of metastatic disease shortly after administration of tamoxifen in ER negative advanced breast carcinoma. A case report Tumori 75(6): 566-569
Brachetti, A.K.; Limburg, H. 1977: Ancillary chemotherapy in the primary treatment of carcinoma of the breast. on the growth pattern of carcinoma of the breast and the establishment of a new concept in treatment Geburtshilfe und Frauenheilkunde 37(2): 109-114
Powles, T.J.; Gordon, C.; Coombes, R.C. 1982: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone Cancer Research 42(8 Suppl): 3458s-3460s
Bardi, M.; Arnoldi, E.; Pizzocchero, G.; Pezzica, E.; Mattioni, D.; Perotti, M. 1994: Endometrioid carcinoma in pelvic endometriosis in a postmenopausal woman with tamoxifen adjuvant therapy for breast cancer. A case report European Journal of Gynaecological Oncology 15(5): 393-395
Sharma, D.; Sharma, U.; Bhatnagar, V.B.; Singh, V.S. 2001: A study of the effect of tamoxifen on serum lipoprotein profiles in premenopausal and postmenopausal women with breast carcinoma and associated risk of cardiovascular disease Indian Journal of Medical Sciences 55(7): 359-365
Di Lorenzo, D.; Zaniboni, A.; Simoncini, E.; Marpicati, P.; Montini, E.; Alghisi, A.; Gorni, F.; Marini, G. 1986: Estrogen and progesterone receptors in neoplastic cells of metastatic pleural effusion of breast carcinoma before and after tamoxifen therapy. Correlation with the clinical response Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 5(4): 232-236
Becher, R.; Höffken, K.; Pape, H.; Schmidt, C.G. 1981: Tamoxifen treatment before orchiectomy in advanced breast cancer in men New England Journal of Medicine 305(3): 169-170